MSB 3.21% $1.13 mesoblast limited

Cell Therapy News/Articles, page-9852

  1. 15,643 Posts.
    lightbulb Created with Sketch. 5711
    So 7 people in ICU in NSW from COVID-19 sadly ... if the age groups are correct from what I have read, then perhaps Mesoblast could undertake a public relations campaign and offer Remestemcel-L for those aged <65yo if their condition(s) deteriorate ? I mean we do have ethics approval for treatment from the last COVID-19 ARDS trial for Sydney Hospitals - just sayin'



    upload_2021-7-7_13-30-58.png
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.